Transaction DateRecipientSharesTypePriceValue
30th January 2020Edward F Smith2,380Open or private sale$2.05$4,879.00
10th January 2020Scott Braunstein26,500Grant/award etc.$0.00
31st December 2019Scott Braunstein31,780Grant/award etc.$0.00
13th December 2019Scott Braunstein100,000Open or private purchase$1.25$125,000.00
29th May 2019Scott Braunstein4,967Grant/award etc.$0.00
16th May 2019Edward F Smith24,211Open or private sale$5.03$121,781.33
18th March 2019Christopher Michael Cashman31,662Exercise of derivative$1.04$32,928.48
29th January 2019Edward F Smith2,492Open or private sale$3.06$7,625.52
28th January 2019Christopher Michael Cashman8,142Open or private sale$3.13$25,484.46
Marinus Pharmaceuticals
Marinus Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw in 2003.

Ticker: MRNS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1267813
Employees: 40
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Cash at Carrying Value: $99 M (8%)
Assets, Current: $109 M (15%)
Property, Plant and Equipment, Net: $2 M (-7%)
Other Assets, Noncurrent: $2 M (-5%)
Assets: $113 M (14%)
Accounts Payable, Current: $4 M (35%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $10 M (18%)
Liabilities: $12 M (11%)
Common Stock, Value, Issued: $123 Th (41%)
Common Stock, Shares, Issued: $122 M (41%)
Retained Earnings (Accumulated Deficit): $279 M (0%)
Treasury Stock, Shares: $292 Th (0%)
Stockholders' Equity (Parent): $101 M (0%)
Liabilities and Equity: $113 M (14%)
Research and Development: $12 M (-56%)
General and Administrative Expenses: $4 M (-48%)
Operating Income/Loss: $16 M (-54%)
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
Mulling Over Marinus Pharmaceuticals

12th February 2021